An Open-label, Multicenter Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Platinum-based Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Adebrelimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; SHR 8068 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 17 Aug 2022 Status changed from not yet recruiting to recruiting.
- 21 Jun 2022 New trial record